NCT03710577

Endocannabinoid and Psychological Responses to Yoga in Healthy Adults

Completed NA Results posted Last updated 8 December 2020

What this trial tests

NA trial testing Yoga in Healthy in 12 participants. Completed in 16 May 2018.

Timeline

12 December 2017

Primary endpoint
16 May 2018

16 May 2018

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	12
Start date	12 December 2017
Primary completion	16 May 2018
Estimated completion	16 May 2018
Sites	1 location across United States

Drugs / interventions tested

• Yoga
• Quiet Rest

Conditions studied

• Healthy — all drugs for Healthy →

Sponsor

University of Wisconsin, Madison

Who can join

Adults 18 to 45, female only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Plasma Concentration of N-arachidonoylethanolamine Primary · This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

Plasma concentration of anandamide, one effector of the endocannabinoid system

Group	Value	95% CI
Yoga	-.013	± .928
Quiet Rest	-.655	± .724

Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG) Primary · This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

Plasma concentration of 2-AG, one effector of the endocannabinoid system

Group	Value	95% CI
Yoga	.032	± .074
Quiet Rest	-.008	± .049

Change in Total Mood Disturbance as Measured by the Profile of Mood States Secondary · This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

65-item self-reported mood questionnaire that measures mood "right now." Scores range from 0-200 with higher scores indicating higher mood disturbance.

Group	Value	95% CI
Yoga	-9.41	± 9.12
Quiet Rest	-7.17	± 14.27

Change in State Anxiety as Measured by the State-Trait Anxiety Inventory Secondary · This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

20-item self-reported anxiety questionnaire that measures anxiety "right now." Scores range from 20-80 with higher scores indicating higher anxiety.

Group	Value	95% CI
Yoga	-1.58	± 10.48
Quiet Rest	-1.92	± 8.40

Change in Total Pain as Measured by the Short-form McGill Pain Questionnaire Secondary · This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)

15-item self-reported pain questionnaire that measures pain "right now." Scores range from 0-45 with higher scores indicating higher pain.

Group	Value	95% CI
Yoga	-1.50	± 1.57
Quiet Rest	0.00	± 2.63

Sponsor's own description

This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.